
|Articles|October 1, 2001
Everchanging STDs offset therapy improvements
'Equal opportunity' diseases strike diverse populations with myriadfrequency, making standardization of tests difficult and unwieldy
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











